FDA Grants Fast Track Designation to Erasca's Oral Pan-RAS Molecular Glue ERAS-0015 for Metastatic Pancreatic Adenocarcinoma

A designation built on seven patients

Fast Track gives Erasca more frequent contact with the agency and, if later criteria are met, a path to rolling review, priority review or accelerated approval. It does not change the approval standard, a point Erasca's own cautionary language makes at length. What the FDA weighed was the July data set, and the denominator deserves stating plainly. The 57% figure comes from seven patients with second-line or later KRAS G12X pancreatic ductal adenocarcinoma who had received a first dose of ERAS-0015 at least eight weeks before the May 25 cut-off at 32 mg once daily, which the company has set as its recommended dose for expansion. Four responses of seven, with unconfirmed responses counted, is what 57% means here. Across all doses, every patient with a confirmed or unconfirmed response remained on treatment at cut-off.

"Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer," said Jonathan E. Lim, M.D., Erasca's chairman, CEO and co-founder. He added that the designation "helps to position us to rapidly advance the clinical development of ERAS-0015, including working closely with FDA on a planned Phase 3 trial in pancreatic cancer, alongside two additional potentially pivotal trials in lung cancer."

Safety numbers from the escalation

Erasca reported no dose-limiting toxicities in the monotherapy cohorts, treatment-related adverse events that were mostly low grade, and no discontinuations attributed to them. Median relative dose intensity was 100% at both 24 mg and 32 mg, meaning the typical patient took every planned dose. The company also disclosed confirmed partial responses at doses as low as 8 mg once daily across several RAS-mutant tumor types, and describes the molecule as designed to inhibit wild-type RAS as well, an approach it says should block the resistance seen with mutant-selective inhibitors.

In colorectal cancer the drug is being combined with panitumumab. No dose-limiting toxicities occurred in four evaluable patients at the 16 mg combination level, backfill enrollment at 16 mg is ongoing, and the 24 mg combination cohort is enrolling under a July 6, 2026 cut-off.

Revolution Medicines in the fine print

The release's forward-looking statement lists, among risks, Erasca's "ability to successfully defend against allegations raised by, or any litigation initiated by, Revolution Medicines (RevMed) that ERAS-0015 infringes patents held by RevMed or was derived from RevMed trade secrets." Erasca offers no further description of those allegations in the Fast Track announcement, and the same sentence appears in its second-quarter results. Revolution Medicines' own pan-RAS inhibitor, daraxonrasib, is in Phase 3 in pancreatic cancer, which makes it the program any Erasca pancreatic trial will be measured against.

Erasca closed June with $384.3 million in cash and marketable securities and then raised $632 million in an upsized public offering in July. The company says that funding covers the three registrational trials it has laid out.

Why This Matters to the APO|APE Reader

The 2027 first-line pancreatic Phase 3 will be the first test of whether a glue that binds every RAS isoform can replace the mutation-by-mutation testing logic that has governed KRAS G12C drugs since sotorasib. AURORAS-1 enrolled on any RAS mutation, and Erasca's pancreatic cohort is described only as KRAS G12X, a category that in this tumor is dominated by G12D, G12V and G12R alleles that no approved inhibitor currently covers. If the design holds, a pancreatic NGS report will need to say "RAS mutant" and little more to qualify a patient, and the eight-week unconfirmed response window that produced the 57% will have to survive confirmation in a much larger denominator before the label can say so.